Sucampo Pharmaceuticals Overview
- Year Founded
-
1996
- Status
-
Acquired/Merged
- Employees
-
139
- Latest Deal Type
-
M&A
- Financing Rounds
-
5
- Investments
-
5
Sucampo Pharmaceuticals General Information
Description
Manufacturer and developer of specialized medicines. The company focuses on the development and commercialization of drugs based on prostones a class of compounds derived from functional fatty acids that occur naturally in the human body that are used for the treatment of chronic and idiopathic constipation, irritable bowel syndrome with constipation and opioid-induced constipation, enabling adult patients to live their lives better.
Contact Information
Website
www.sucampo.comCorporate Office
- 805 King Farm Boulevard
- Suite 550
- Rockville, MD 20850
- United States
Corporate Office
- 805 King Farm Boulevard
- Suite 550
- Rockville, MD 20850
- United States
Sucampo Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sucampo Pharmaceuticals Comparisons
Industry
Financing
Details
Sucampo Pharmaceuticals Competitors (50)
One of Sucampo Pharmaceuticals’s 50 competitors is Gilead, a Formerly VC-backed company based in Foster City, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Swedish Orphan Biovitrum | Formerly VC-backed | Stockholm, Sweden | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Incyte | Formerly VC-backed | Wilmington, DE | ||||
| Bristol-Myers Squibb | Corporation | Princeton, NJ |
Sucampo Pharmaceuticals Patents
Sucampo Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2004062669-A1 | Use of a macrolide compound for treating dry eye | Inactive | 16-Jan-2003 | ||
| US-20040198763-A1 | Usign tacrolimus; eye drops | Inactive | 16-Jan-2003 | ||
| JP-2011012071-A | Pharmaceutical composition containing fk506 derivative for treating allergic disease, and use thereof | Pending | 09-Aug-2002 | ||
| AU-2003256068-A1 | Pharmaceutical compositions comprising fk506 derivatives and the ir use for the treatment of allergic diseases | Inactive | 09-Aug-2002 | ||
| EP-1536793-A1 | Pharmaceutical compositions comprising fk506 derivatives and the ir use for the treatment of allergic diseases | Inactive | 09-Aug-2002 | A61K31/4745 |
Sucampo Pharmaceuticals Signals
Sucampo Pharmaceuticals Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Sucampo Pharmaceuticals Investments & Acquisitions (5)
Sucampo Pharmaceuticals’s most recent deal was a Later Stage VC with Cancer Prevention Pharmaceuticals for . The deal was made on 14-Sep-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cancer Prevention Pharmaceuticals | 14-Sep-2017 | Later Stage VC | Drug Discovery | ||
| Vtesse | 03-Apr-2017 | Merger/Acquisition | Drug Discovery | ||
| R-Tech Ueno | 22-Oct-2015 | PIPE | Drug Delivery | ||
| R-Tech Ueno | 13-Oct-2015 | Merger/Acquisition | Drug Delivery | ||
| Sucampo | 29-Dec-2010 | Merger/Acquisition | Drug Discovery |
Sucampo Pharmaceuticals Exits (1)
Sucampo Pharmaceuticals’s most recent exit was on 14-Sep-2017 from Cancer Prevention Pharmaceuticals. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Cancer Prevention Pharmaceuticals | 14-Sep-2017 | Completed |
|
Sucampo Pharmaceuticals FAQs
-
When was Sucampo Pharmaceuticals founded?
Sucampo Pharmaceuticals was founded in 1996.
-
Where is Sucampo Pharmaceuticals headquartered?
Sucampo Pharmaceuticals is headquartered in Rockville, MD.
-
What is the size of Sucampo Pharmaceuticals?
Sucampo Pharmaceuticals has 139 total employees.
-
What industry is Sucampo Pharmaceuticals in?
Sucampo Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Sucampo Pharmaceuticals a private or public company?
Sucampo Pharmaceuticals is a Private company.
-
What is the current valuation of Sucampo Pharmaceuticals?
The current valuation of Sucampo Pharmaceuticals is .
-
What is Sucampo Pharmaceuticals’s current revenue?
The current revenue for Sucampo Pharmaceuticals is .
-
How much funding has Sucampo Pharmaceuticals raised over time?
Sucampo Pharmaceuticals has raised $306M.
-
Who are Sucampo Pharmaceuticals’s investors?
Astellas Pharma, Athyrium Capital Management, MCP Capital, Mitsubishi UFJ Capital, and Nissay Capital are 5 of 9 investors who have invested in Sucampo Pharmaceuticals.
-
Who are Sucampo Pharmaceuticals’s competitors?
Gilead, Swedish Orphan Biovitrum, Merck & Co., Incyte, and Bristol-Myers Squibb are some of the 50 competitors of Sucampo Pharmaceuticals.
-
When was Sucampo Pharmaceuticals acquired?
Sucampo Pharmaceuticals was acquired on 01-Feb-2018.
-
Who acquired Sucampo Pharmaceuticals?
Sucampo Pharmaceuticals was acquired by Mallinckrodt Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process